Status:
COMPLETED
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Lead Sponsor:
Genentech, Inc.
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma...
Eligibility Criteria
Inclusion
- Histologically documented ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma that has recurred \> 6 months after platinum-based chemotherapy
- This must be the first recurrence of the epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma
- Are at least two weeks but no more than 3 months after the completion of second-line cytotoxic chemotherapy
- Are currently under observation or being treated with bevacizumab as a second-line maintenance therapy
- Have a valid email address and access to the internet
- Provide voluntary written informed consent
- Speak and read English fluently
Exclusion
- Current participation in a blinded clinical trial for ovarian cancer treatment. (Participation in a trial involving only supportive care medicines and/or growth factors is acceptable)
- Another primary diagnosis of cancer in a different site
Key Trial Info
Start Date :
June 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT01422265
Start Date
June 1 2011
End Date
April 1 2015
Last Update
November 2 2016
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Goodyear, Arizona, United States, 85338
2
Phoenix, Arizona, United States, 85013
3
Tucson, Arizona, United States, 85724
4
Salinas, California, United States, 93901